Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Oct;51(4):378-9.
doi: 10.1097/MPG.0b013e3181ecf3d4.

Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children

Ariel E Feldstein, Valerio Nobili
Editorial

Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children

Ariel E Feldstein et al. J Pediatr Gastroenterol Nutr. 2010 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Diagnostic Target Discovery in NAFLD
The understanding of pathophysiologic pathways involved in liver damage and fibrosis in NAFLD can be used to develop mechanism-base biomarkers. In the context of lipid overloading of hepatocyte the different lipid types and metabolites accumulating may play an important role in triggering lipotoxicity (1) and NASH development. Mitochondrial dysfunction is a key feature of NASH and different mechanisms have been proposed including an increased production of ROS (2), and mitochondrial outer membrane permeabilization, resulting in a cascade of events leading to inflammation (3), hepatocellular apoptosis (4), fibrogenesis and fibrosis (5). Abbreviations: ROS, reactive oxygene species; HSC, activated stellate cells.
See this image and copyright information in PMC

Comment on

References

    1. Nobili V, Day C. Childhood NAFLD: a ticking time-bomb? Gut. 2009;58(11):1442. - PubMed
    1. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46(2):582–9. - PubMed
    1. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008;28(4):386–95. - PubMed
    1. Fitzpatrick E, Mitry R, Quaglia A, Hussain M, deBruyne R, Dhawan A. Serum level of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. JPGN-Europe-D-09-00386. (In press) - PubMed
    1. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072–8. - PMC - PubMed